US Patent Issued to Regeneron Pharmaceuticals on Nov. 18 for "Intralesional administration of PD-1 inhibitors for treating skin cancer" (New York Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,473,364, issued on Nov. 18, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Intralesional administration of PD-1 inhibitors for treating skin cancer" was invented by Matthew G. Fury (New York) and Israel Lowy (Dobbs Ferry, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure relates to methods for treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with a skin cancer and intralesionally administering to the tumor of the subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an antibody or antigen-binding fragment thereof that sp...